{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-229770","form_type":"8-K","ticker":"BHC","cik":"0000885590","company_name":"Bausch Health Companies Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.877163+00:00","generated_at":"2026-06-10T23:42:30.790766+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bausch + Lomb provides financial details for planned acquisition of Novartis eye-care assets","bullets":["Deal: $1.75B upfront plus up to $750M milestones for Xiidra, AcuStream, SAF312, OJL332.","Acquired assets generated $487M net revenue in 2022 and $468M in 2021.","Acquisition expected to close at or around end of September 2023, subject to conditions.","Audited and unaudited abbreviated financial statements of acquired assets furnished as exhibits."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-229770","json":"https://secwatch.observer/filing/0001193125-23-229770.json","markdown":"https://secwatch.observer/filing/0001193125-23-229770.md","text":"https://secwatch.observer/filing/0001193125-23-229770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885590/000119312523229770/0001193125-23-229770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885590/000119312523229770/d547838d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:42:30.790766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}